KEYTRUDA® is indicated for:
- First-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) as monotherapy, in adult patients whose tumours have PD-L1 expression [Combined Positive Score (CPS) ≥ 1] as determined by a validated test.
- First-line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) in combination with platinum and fluorouracil (FU) chemotherapy, in adult patients.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®*) recommendation for head and neck squamous cell carcinoma (recurrent, unresectable or metastatic disease [with no surgery or radiotherapeutic option])2
- Pembrolizumab monotherapy is a preferred first-line regimen treatment option for patients with CPS ≥1 (category 1 if CPS ≥20).
- Pembrolizumab/platinum (cisplatin or carboplatin/5-FU) therapy is a preferred first-line regimen treatment option.
See the complete NCCN Clinical Practice Guideline recommendations for head and neck cancer
NCCN=National Comprehensive Cancer Network*.
* All other trademarks are the property of their respective owner(s).
References:
1. Merck Canada Inc. KEYTRUDA® Product Monograph. April 19, 2023.
2. National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Head and Neck Cancers, version 2. 2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf
CA-OHN-00038